Angiopoietin-like 4 Blocking Peptide peptide (STJ505612)

SKU:
STJ505612-250

Shipping:
Free Shipping
Current Stock:
Applications: Immunodepletion/Immunocompetition
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Angiopoietin-like 4 Blocking Peptide is synthetically produced from the 50-100 sequence and is suitable for use in western blot applications.
Formulation: Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice.
Dilution Range: WB: 1:2, 500-1:5, 000
Storage Instruction: Store at-20°C for long term storage. Avoid freeze-thaw cycles.
Gene Symbol: Angptl4
Gene ID: 57875
Uniprot ID: ANGL4_MOUSE
Immunogen Region: 50-100
Immunogen: Synthetic peptide taken within amino acid region 50-100 on mouse Angiopoietin-related protein 4.
Tissue Specificity Detected in liver and kidney. Predominantly expressed in adipose tissue and is strongly up-regulated by fasting in white adipose tissue and liver.
Post Translational Modifications N-glycosylated. ANGPTL4 N-terminal chain: Forms disulfide-linked dimers and tetramers. Cleaved into a smaller N-terminal chain and a larger chain that contains the fibrinogen C-terminal domain.both cleaved and uncleaved forms are detected in the extracellular space. The cleaved form is not present within the cell.
Function Mediates inactivation of the lipoprotein lipase LPL, and thereby plays a role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism. May also play a role in regulating glucose homeostasis and insulin sensitivity. Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage. Upon heterologous expression, inhibits the adhesion of endothelial cell to the extracellular matrix (ECM), and inhibits the reorganization of the actin cytoskeleton, formation of actin stress fibers and focal adhesions in endothelial cells that have adhered to ANGPTL4-containing ECM (in vitro). Depending on context, may modulate tumor-related angiogenesis (Probable). ANGPTL4 N-terminal chain: Mediates inactivation of the lipoprotein lipase LPL, and thereby plays an important role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism. Has higher activity in LPL inactivation than the uncleaved protein.
Peptide Name Angiopoietin-Related Protein 4
425o18-1
Angiopoietin-Like Protein 4
Fasting-Induced Adipose Factor
Hepatic Fibrinogen/Angiopoietin-Related Protein
Hfarp
Secreted Protein Bk89 Cleaved Into - Angptl4 N-Terminal Chain - Angptl4 C-Terminal Chain
Database Links Reactome: R-MMU-8963889
Reactome: -MMU-9762292
Cellular Localisation Secreted
Extracellular Space
Extracellular Matrix
The Unprocessed Form Interacts With The Extracellular Matrix
This May Constitute A Dynamic Reservoir
A Regulatory Mechanism Of The Bioavailability Of Angptl4
Alternative Peptide Names Angiopoietin-Related Protein 4 protein
425o18-1 protein
Angiopoietin-Like Protein 4 protein
Fasting-Induced Adipose Factor protein
Hepatic Fibrinogen/Angiopoietin-Related Protein protein
Hfarp protein
Secreted Protein Bk89 Cleaved Into - Angptl4 N-Terminal Chain - Angptl4 C-Terminal Chain protein
Angptl4 protein
Farp protein
Fiaf protein
Ng27 protein

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance